A Phase 1 And 2a Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity And Antitumor Activity Of LAVA-051 In Patients With Relapsed Or Refractory CD1d-Positive Chronic Lymphocytic Leukemia, Multiple Myeloma Or Acute Myeloid Leukemia Read more
A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma Read more
Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma Read more
A Phase 2, Multicohort Open-Label Study Of JNJ-68284528, A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA In Subjects With Multiple Myeloma (CARTITUDE 2) Read more
A Phase 1/2, Multicenter, Dose-Escalation And Expansion Study Of Combination Therapy With Venetoclax, Daratumumab And Dexamethasone (With And Without Bortezomib) In Subjects With Relapsed Or Refractory Multiple Myeloma Read more
Clinical Grade Molecular Profiling Of Patients With Multiple Myeloma And Related Plasma Cell Malignancies Read more
A Phase 2B Study Of Selinexor (KPT-330), In Combination With Carfilzomib, Daratumumab Or Pomalidomide In Patients With Multiple Myeloma Relapsing On Current Therapy Read more
